- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Public's Opinion of Supreme Court Drops After Health Care Law Decision
Supreme Court
health care overhaul
The American public’s satisfaction with the , which had already been low by historical standards in recent polls, dropped further in the wake of the court’s 5-to-4 ruling last month upholding President Obama’s law.
The nation is now evenly divided, with 41 percent of Americans saying they approve of the job the court is doing and the same share voicing disapproval, according to a new poll conducted by The New York Times and CBS News. In a poll a few weeks before the health care decision, the court’s approval rating was 44 percent and its disapproval rating 36 percent.
Read the full story: http://tinyurl.com/cxdzfu9
Source: The New York Times
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
